- Conditions
- Chronic Shift Work Sleep Disorder
- Interventions
- PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 13,084
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Photoaging, Wrinkle, Skin Laxity
- Interventions
- Hybrid Fractional Laser, Facial Cleanser, Facial Moisturizer, Sunscreen
- Procedure · Other
- Lead sponsor
- Revision Skincare
- Industry
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Dallas, Texas
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Interventions
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
- Conditions
- Hemostasis
- Interventions
- Fibrinogen Concentrate (FC), Cryoprecipitate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
- Interventions
- electrophysiology study and ablation with an Abbott Ablation Catheter
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Rancho Mirage, California + 16 more
- Conditions
- Spinal Cord Injuries, Tetraplegia
- Interventions
- bihemispheric transcranial pulsed current stimulation (tPCS), unihemispheric transcranial pulsed current stimulation (tPCS), bihemispheric transcranial direct current stimulation (tDCS), unihemispheric transcranial direct current stimulation (tDCS), sham-control
- Other
- Lead sponsor
- Shepherd Center, Atlanta GA
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
- Conditions
- Leiomyoma, Uterine Hemorrhage
- Interventions
- Ulipristal acetate (UPA), Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more
- Conditions
- Venous Thrombosis
- Interventions
- Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention
- Other
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
- Conditions
- Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
- Interventions
- Tofersen, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more
- Conditions
- Astrocytoma, Glioblastoma, Oligodendroglioma
- Interventions
- Craniotomy, Quantitative Oblique Back-Illumination Microscopy
- Procedure · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
- Interventions
- Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Parkinson's Disease
- Interventions
- UCB0599, Placebo
- Drug
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 45
- States / cities
- La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
- Conditions
- Cardiovascular Disease and Lipoprotein(a)
- Interventions
- TQJ230, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 287
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
- Conditions
- Staphylococcus Aureus
- Interventions
- Not listed
- Lead sponsor
- Solventum US LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Decatur, Georgia + 5 more
- Conditions
- Covid19
- Interventions
- Placebo, Metformin
- Other · Drug
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 3,214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 110
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
- Conditions
- Breast Neoplasms
- Interventions
- exemestane, sunitinib malate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Migraine Disorders
- Interventions
- ALD403, Placebo
- Biological
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 82
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more
- Conditions
- Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 25
- States / cities
- Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more